Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04830137 · ClinicalTrials.gov registry record · Phase 1

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

A Phase 1 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), sponsored by Nurix Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
248
Enrollment target
16
Study locations

NCT04830137: Recruiting Phase 1 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), sponsored by Nurix Therapeutics.

NCT04830137 is a Phase 1 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) that is actively recruiting participants, run by Nurix Therapeutics. The registered enrollment target is 248 participants, above the 183-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (36% higher). The trial reports 16 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04830137, a Phase 1 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), is actively recruiting participants, sponsored by Nurix Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
248 participants
Enrollment target
16
Study locations

Study Summary

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.

Primary Outcome

Phase 1a

Conditions Studied

Chronic Lymphocytic Leukemia (CLL) Small Lymphocytic Lymphoma (SLL) Diffuse Large B Cell Lymphoma (DLBCL) Follicular Lymphoma (FL) Mantle Cell Lymphoma (MCL) Primary Central Nervous System Lymphoma (PCNSL) Marginal Zone Lymphoma (MZL) Waldenstrom Macroglobulinemia (WM)

Interventions

  • DRUG NX-2127

Study Locations (16)

California

  • City of Hope - Duarte
  • University of California Irvine - Orange
  • University of California San Francisco Medical Center - San Francisco

Florida

  • Mount Sinai Comprehensive Cancer Center - Miami Beach
  • Sarah Cannon Research Institute at Florida Cancer Specialists - Sarasota

Ohio

  • University of Cincinnati Medical Center - Cincinnati
  • OSU Wexner Medical Center - Columbus

Texas

  • Baylor University Medical Center - Dallas
  • MD Anderson Cancer Center - Houston

Colorado

  • Sarah Cannon Research Institute at Colorado Blood Cancer Institute - Denver

Illinois

  • The University of Chicago Medical Center - Chicago

Maryland

  • National Institutes of Health Clinical Center - Bethesda

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 248 participants
Start Date 2021-05-05
Est. Completion 2027-05
Phase Phase 1
Nurix Therapeutics

8 total trials

What NCT04830137 shows while recruiting

NCT04830137 is an interventional study that assigns participants to a tested intervention. The registered 248 participants enrollment target is mid-sized for trials with a published cap, above the 183-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (36% higher).

The record links to 8 conditions, with Chronic Lymphocytic Leukemia (CLL) appearing as the primary indexed condition, and to 1 intervention - of which NX-2127 is the first listed.

NCT04830137 lists 16 locations in 11 states (California, Florida, Ohio).

Frequently Asked Questions

What is clinical trial NCT04830137 about?

NCT04830137 is a clinical study titled "A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies". This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.

What is the current status of trial NCT04830137?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 248 participants. The study started on 2021-05-05. Estimated completion is 2027-05.

What conditions does trial NCT04830137 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL).

What interventions are being tested in trial NCT04830137?

The interventions under investigation include: NX-2127 (DRUG).

Who is sponsoring clinical trial NCT04830137?

This trial is sponsored by Nurix Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04830137 being conducted?

This trial has 16 study locations across California, Colorado, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Lymphocytic Leukemia (CLL)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04830137's enrollment target sits among peer trials

248 5th of 29 higher than 25 of 29 other Chronic Lymphocytic Leukemia (CLL) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia (CLL) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04577911 · 248 participants

    How is Social Connection Represented in the Brain?

  • NCT04777994 · 248 participants · Phase 1

    Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

  • NCT04792489 · 248 participants · Phase 2

    DALY II USA/ MB-CART2019.1 for DLBCL

  • NCT05398185 · 248 participants · NA

    WiseApp for Spanish Speakers Living With HIV

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT04830137

Source: ClinicalTrials.gov NCT04830137, the US trial registry maintained by the National Library of Medicine. NCT04830137 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.